Checkpoint Therapeutics is an oncology company that focuses on the acquisition, development, and commercialization of treatments for solid tumor cancers. Its lead product candidates include Cosibelimab, CK-302, and Olafertinib. The company is also collaborating with TG Therapeutics to develop and commercialize certain assets in the field of hematological malignancies.